Patients with affective disorders profit most from telemedical treatment: Evidence from a naturalistic patient cohort during the COVID-19 pandemic Tobias Rohrmann<sup>1†</sup>, Peter Praus<sup>1†</sup>, Tanja Proctor<sup>2†</sup>, Anastasia Benedyk<sup>1</sup>, Heike Tost<sup>1</sup>, Oliver Hennig<sup>1</sup>, Andreas-Meyer-Lindenberg<sup>1</sup>, Anna-Sophia Wahl<sup>1,3\*</sup> <sup>1</sup>Central Institute of Mental Health, University of Heidelberg, J5, 68159 Mannheim, Germany <sup>2</sup>Institute of Medical Biometry (IMBI), University of Heidelberg, Im Neuenheimer Feld 130.3, 69120 Heidelberg, Germany <sup>3</sup>Brain Research Institute, University of Zurich, Winterthurerstr. 190, 8057 Zurich, Switzerland †shared first authorship Corresponding author: anna-sophia.wahl@zi-mannheim.de Keywords: Telemedicine, psychiatry, depression, well-being, chronic disorders 

Abstract

28

- Background: During the COVID-19 pandemic telemedicine became essential in maintaining diagnostic procedures and treatment in psychiatry. However, it is still an open question if telemedicine is a feasible treatment option for all groups of psychiatric patients alike. This prospective monocentric observational trial was conducted to assess the general applicability of telemedical treatment in a
- naturalistic psychiatric outpatient cohort and to identify groups of disorders and clusters of psychopathology that respond particularly well to telemedical treatment considering sociodemographic
- 35 characteristics and patients' perspectives.
- 36 Methods: Patients were recruited April 2020 April 2021 and asked to fill out the WHO-5 and the
- 37 SCL-90R at baseline, after 4-6 and 8-12 weeks and a feedback-survey. Additionally, medical records,
- 38 psychopathology, psychosocial functioning and sociodemographic data were analyzed. Primary
- 39 outcomes were well-being, psychopathology and functioning during treatment. Secondly, diagnostic
- 40 groups and psychopathology linked to a superior treatment-response were determined with respect to
- 41 patients' subjective experiences.
- 42 *Results:* Out of 1.385 patients, 254 mostly with hyperkinetic (35.3%) and depressive disorders
- 43 (24.6%) took part. Well-being and SCL-90R total scores improved substantially (both p<0.001). CGI
- and GAF scores were worse in depressed subjects (both p<0.05). Improvement was mainly seen in
- 45 depressed patients; chronic disorders experienced a decline in well-being. Sociodemographic
- characteristics could not explain this difference. Particularly female (r=0.413) patients found
- 47 telepsychiatry equivalent to conventional treatment. The more virtual sessions participants attended
- 48 the more likely they were to find telepsychiatry equal to conventional treatment (r=0.231).
- 49 *Conclusions:* Telemedicine is an effective treatment for patients with depression under naturalistic
- 50 conditions. Telemedical consultations are a simple and reliable way of monitoring symptom severity
- and directing treatment choices during the treatment of depressive disorders. Patients with depression
- 52 benefited more from telemedical treatment compared to participants with chronic non episodic
- 53 psychiatric disorders. Future research needs to concentrate on improving telemedical treatment options
- suited for the latter conditions. Psychiatric telemedicine yielded overall high degrees of satisfaction
- 55 among users.

56575859

60

## Introduction

68

69

70

71 72

73 74

75

76

77 78

79

80

81

82

83 84

91

92 93

94

95 96

97

98 99

100 101

102

103

104 105

106

107

108

Already at early stages of the coronavirus disease 19 (COVID-19) pandemic it became evident that an accelerated transition from face-to-face services to virtual interventions would automatically impose a plethora of critical questions concerning the adequacy and quality of such treatment options on healthcare providers, caregivers and patients alike(1). Telemedicine - in contrast to conventional psychiatric care - solely relies on the exclusive administration of mental health services via various technological devices and platforms without face-to-face contact(2). Pre-pandemic investigations had substantially focused on the applicability and potential benefits of telemedical mental health services in the context of equalizing access to these services under conditions of shortage, mainly targeting symptoms of depressive or anxiety disorders(3,4). The rapid expansion of telemedical interventions related to the COVID-19 pandemic raised the question of their comparability with conventional treatment options, hitherto mainly relying on personal relationships in the field of psychiatry and psychotherapy. Until 2020, the available data showed a steadily growing dissemination of telemedical practice, albeit only accounting for a relatively small proportion of the entirety of medical services in the U.S.(5). With the pandemic surge of COVID-19 infections in 2020, sudden changes in legislation and reimbursement practices allowed for an unprecedented expansion of telemedical treatment services in the field of psychiatry(6,7).

85 Besides of general advantages of telemedical treatment such as greater geographical and temporal flexibility, the reduction of age-, gender- and ethnicity-specific treatment barriers(8) and cost 86 effectiveness(9), telemedical interventions were an essential tool in maintaining the continuity of 87 88 community-based treatment paths for patients with severe mental health conditions like schizophreniaspectrum disorders during the COVID-19 pandemic(10). Telemedical interventions also promoted the 89 90 involvement of peers and relatives at multiple stages of diagnostic and treatment procedures (11).

Despite these advantages, there are some valid concerns about possible tool-related limitations of the reliability and reproducibility of telemedical assessments and categorical diagnostics under the conditions of telemedical consultations compared to traditional face-to-face evaluations (12). In particular, there is only limited evidence on the question which mental health conditions might respond optimally to exclusive telemedical treatment and which mental disorders require face-to-face appointments, respecting patients' personal preferences. On a larger scale, telemedical interventions alone might not be suited to mitigate or overcome gross disparities in health status and access to mental health services, rather calling for thorough systematic implementation of telemedical services without marginalizing patient groups with less developed digital literacy(13).

In this longitudinal observational study, the authors aimed to elucidate the applicability, reliability and safety of telemedical assessment and treatment in a naturalistic sample of psychiatric outpatients during the COVID-19 pandemic. In this line, the purpose of this study was to identify a cluster of mental disorders and patient related features (e.g. sociodemographic characteristics) that potentially indicate a favorable response to telemedical treatment under these conditions and to determine the comparability of telemedical interventions to conventional treatments from a patient-perspective.

## Methods

# Study design

- The study was designed during the first enforced Germany-wide lockdown (starting from March 22 109
- 2020) due to the COVID-19 pandemic. Most services of the outpatient clinic at the Central Institute of 110

Mental Health, Mannheim (CIMH) at the University of Heidelberg had to be transformed into 111 telemedical treatment options in order to maintain provision of psychiatric consultations for patients 112 with mental health issues despite severe contact restrictions. The goal of the study was (1) to observe 113 114 how psychiatric symptoms of patients with mental health problems develop during the course of telepsychiatry; (2) if patient cohorts could be identified which benefit more or less from telemedical 115 psychiatric treatment, (3) if sex-, age or sociodemographic factors with an impact on the effectiveness 116 of telepsychiatric treatment could be revealed and (4), how patients experienced telepsychiatric 117 consultations compared to conventional treatment face to face with professional mental health experts. 118

Participants were recruited between April 2020 and April 2021. Patients received information about the study during the scheduling of their first telemedical psychiatric counseling. The aims and purpose of the study were explained either by members of the study team who contacted interested patients or by the psychiatrist or psychologist who provided the first telemedical session. Patients who gave informed consent to participate were asked to complete three surveys during the course of the study: Before the start of the first telemedical consultation participants agreed that their medical record which would be created during telemedical treatment could be used for further analysis (see below) as part of the study. Subjects were also asked to fill out the WHO-5 well-being index (WHO-5(14)) and the symptom check-list-90-R (SCL-90R(15)), which were provided paper-based. 4-6 and 8-12 weeks after the first telemedical counseling session, participants could choose for the second and third survey, if they preferred an interview via phone call or online surveys using REDCap (https://www.projectredcap.org/), a secure web application for building and managing online surveys for research studies and operations supported by the National Institutes of Health (NIH/NCATS UL1 TR000445). N=254 participants returned the first paper-based survey (including 9 anonymous study subjects). N=94 participated in the second survey via RedCap and N=50 via telephone. N=68 study subjects also completed the third survey via RedCap, while N=48 were interviewed via telephone. During the second and third survey patients were asked to fill out the WHO-5 questionnaire again while participants were only requested twice to complete the SCL90-R (1st and 2nd survey). Either during the second or the third survey patients could evaluate the telemedical psychiatric counseling (see details below).

# Acquisition psychiatric history and sociodemographic data

N=182 subjects (71.7%) gave informed consent to acquire sex, age and sociodemographic data as well as psychiatric history and psychopathological symptoms from the medical record. All professional experts providing telepsychiatric services in our outpatient clinic were instructed to use a structured form in the computerized documentation system of our clinic (ORBIS, SAP, Walldorf Germany) for the first interview. Patients were asked for current psychiatric symptoms, psychiatric diagnoses according to the ICD-classification of the WHO (version 10), past psychiatric history and sociodemographic data such as current life and living situation, education, professional training and labor situation, debts and history of criminal assaults. All psychiatrists and psychologists of our outpatient clinic were also requested to score patients on initial appearance according to the global assessment of functioning scale (GAF(16)) and the clinical global impression scale (CGI(17)). For later data analysis electronic medical records were systematically queried for the number of telemedical treatment sessions participants received and possible hospitalizations during the course of the study. Medical records were additionally scrutinized for the number of in- and outpatient treatments and days of hospitalization during the year before March 2020, when outpatient psychiatric care was still provided personally.

119

120 121

122 123

124

125

126

127

128 129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146 147

148

149 150

151

Evaluation and follow-up of psychopathological symptoms 155

# WHO-5 Well-Being Index (WHO-5)

- For assessment of overall well-being over the course of telepsychiatric counseling the WHO-5, a short 157
- self-administered measure of well-being over the last two weeks(18), was used. The WHO-5 consists 158
- of five positively worded items that are rated on a 6-point Likert scale, ranging from 0 (at no the time) 159
- to 5 (all of the time). We transformed the raw scores to a score from 0 to 100 (raw data\*4), where lower 160
- scores indicated worse well-being. A score of ≤50 was considered as poor wellbeing and a score of 28 161
- or below indicative of depression. 162

## SCL-90-R 163

156

- The SCL-90-R by Derogatis(19) measures the subjective perception of physical and mental symptoms 164
- a person has experienced during the past seven days. All 90 symptoms are scored on a Likert scale 165
- consisting of 5 steps, ranging from 0 (the symptom is not there at all) to 4 (indicating very strong 166
- impairment due to the symptom). We analyzed the data gained in two surveys of the SCL-90-R 167
- according to the instructions provided by Derogatis/Franke, German Version, 2<sup>nd</sup> Edition, Beltz Test, 168
- 2000. T-Values equal to and above 60 were considered as a relevant mental detraction from the 169
- 170 respective symptom or global score.

## Clinical Global Impression Scale (CGI) and the global assessment of functioning scale (GAF) 171

- While the WHO-5 and the SCL-90-R are self-report questionnaires on the subjective perception of 172
- 173 overall well-being and different symptom domains, the GAF and CGI were used as clinician-rated
- scales to document the global impairment due to patients' (mental) health conditions. The CGI scores 174
- the severity of the symptoms, ranging from 1 to 7 (1= normal/not at affected; 7=very severely ill(17)). 175
- 176 The GAF indicates the global functioning of a patient taking into account the psychiatric, social and
- professional level. The scale is ranging from 0 (very sick) to 100 (healthy)(16). 177

## Evaluation of telemedicine by participants 178

- 179 N=112 (44.1% of all participants) completed an evaluation questionnaire asking for feedback
- concerning technical details (e.g. if patients decided for phone call or video conference or both and if 180
- interruptions occurred due to technical problems) and the overall experience with the telepsychiatric 181
- consultations. Participants were asked how helpful they found the telemedical intervention and if it 182
- was comparable to a conventional face-to face contact. Patients were also requested to state their 183
- preference about using telepsychiatry in the future again. Participants could also document pros and 184
- 185 cons of the telemedicine and their wishes for future improvements.

## Data analysis

- 187 All data acquired during surveys and from the medical records were entered into an Excel master file
- 188 and then translated to SPSS Version 27 and R Version 4.1.1. for further analysis. The descriptive
- 189 statistics of the sample were computed for the sociodemographic characteristics, consisting of
- frequencies and percentages for categorical values and mean and standard deviations (SD) for scale 190
- 191 variables. Differences between two groups of patients (depressive and suffering from other psychiatric
- diseases) were assessed using the Mann-Witney test for the different non-parametric clinical scale 192
- variables. The differences in these scales over time for the single patients were assessed with an 193
- 194 ANOVA test and a post-hoc Bonferroni test.

- 195 A paired Wilcoxon signed-rank test was used to assess differences in the levels of mental health
- variables such as e.g.: WHO-5 or SCL 90 comparing the results of the three inquiries. Bivariate 196
- associations between WHO-5 and SCL90-R, CGI and GAF were analyzed using linear regression 197
- models and between mental x and y (continuous variable) were assessed via Spearman's correlation 198
- coefficient r. For all tests, a p-value of less than 0.05 was considered statistically significant. 199

# Ethics Approval and Consent to Participate

- 201 Written informed consent was obtained from all subjects who participated in our study, except for 9
- cases where patients sent the paper-based WHO-5 and SCL90-R questionnaires of the first survey back 202
- to us anonymously. These data could not be further evaluated. The study design and data acquisition 203
- 204 were presented to the ethics committee II at the medical faculty Mannheim, University of Heidelberg
- 205 and approved (No. 2020-562N).

## **Results**

200

206

214

- 207 During the first year of the Covid-19 pandemic (April 2020 - April 2021) 8.235 telemedical treatment
- sessions were provided to 1.385 patients via phone or video call by the psychiatrists and psychologists 208
- 209 of the outpatient clinic at the Central Institute of Mental Health (CIMH) in Mannheim, Germany. 254
- 210 (18.3%) of these patients gave their informed consent to participate in our study and to use their medical
- record generated during telemedical treatment for further systematic analysis. Out of 239 patients who 211
- engaged in the first survey at baseline, 140 patients responded to the second, and 103 patients to the 212
- 213 third survey 4-6 and 8-12 weeks after the first telemedicine session, respectively.

# Demographics and psychiatric history

- In total, electronic medical records of 174 patients could be evaluated revealing sociodemographic 215
- 216 characteristics as presented in Table 1: Our study population consisted of younger adults,  $38.6 \pm 13.1$
- years old with more women (56.7%,  $39.9 \pm 13.3$  years old) than men (37,8%,  $37.0 \pm 12.6$  years old) 217
- participating. Most patients had a partner (55.3%), but no children (82.8%) and were living alone 218
- 219 (53.6%). Almost half of the study population (48.8%) was well educated with at least 12 years of school
- education while more than half (53.8%) had also successfully completed apprenticeship. 53.3% were 220
- employed during the time of the telemedicial counseling and most patients (63.9%) lived in a stable 221
- 222 financial situation without significant debts.
- All patients included in the study were diagnosed with at least one psychiatric disorder (Table 2): The 223
- largest group (35.3%) consisted of patients with hyperkinetic and tic disorders, while almost a quarter 224
- 225 of the study population (24.6%) was primarily diagnosed with a depressive episode or recurrent
- 226 depressive disorder according to ICD-10. In addition, for 32 patients (12,6%) a depressive or recurrent
- depressive disorder was noted as secondary diagnosis. Schizophrenia was only diagnosed in 3 cases 227
- (1.3%) as a main psychiatric disorder justifying current psychiatric treatment. Matching with this 228
- 229 preponderance of affective and neurodevelopmental disorders, most patients presented with
- psychopathological symptoms (Supplementary Table 1) typical of affective and hyperkinetic disorders 230
- such as attention (51.9%) and concentration deficits (67.6%), abnormal thought processes (71.7%), 231
- 232 changes in mood (84.0%), reduced ability to experience joy (52.9%), lack of drive (56.9%), anxiety
- (64.4%) and sleep disturbances (69.4%). Orientation, mnestic functioning as well as illness insight 233
- 234 were undisturbed in almost all patients (see Supplementary Table 1), while symptoms typical of an
- 235 episode of psychosis such as abnormal thought content, hallucinations or intrusions were almost absent
- 236 (Supplementary Table 1). Among the patients who gave full particulars of their psychiatric medical

- 237 record (28.3%), 29.2% reported a history of attempted suicides. Three quarters of participants (74.3%)
- had been already treated for psychiatric issues in the past, while only a minority (25.8%) received 238
- 239 psychiatric treatment for the first time.
- Most patients (93,7%, Table 3) had not been in contact with our outpatient clinic within 12 months 240
- 241 before the pandemic. During the course of the study patients had on average 4 (4.26  $\pm$  5.45) psychiatric
- appointments. At least 3 (3.05  $\pm$  3.58) appointments were provided via phone or video call. For 242
- 243 comparison, the 16 patients that had already been in psychiatric outpatient treatment before the
- 244 pandemic had also had 4  $(4.56 \pm 5.89)$  face to face appointments during the course of 12 months before
- 245 the pandemic. Only a small number of participants (n=13, 5.12%) required hospitalization during the
- study period. These 13 patients spent on average  $74.54 \pm 46.67$  days on a psychiatric ward (Table 3), 246
- 247 while four participants had stayed in hospital more than 4 months (128  $\pm$  62.20) in the year prior to the
- 248 pandemic.

## Changes of psychopathology according to WHO-5 and SCL90 self-assessment under telemedicine 249

- psychiatry 250
- Subjects were requested to report current mental well-being by completing the WHO-5 Well-Being 251
- Index (WHO-5,(18)) before, as well as 4-6 and 8-12 weeks after the beginning of telepsychiatric 252
- treatment. 237 patients (93.3%) participated in the first self-report, scoring 31.65  $\pm$  20.11 (range 0-100, 253
- Fig. 1A). The prevalence of poor well-being (WHO-5 score<50, (20)) was 81.9% (n=194) and that of 254
- depression (WHO-5 score<28) was 55.3% (n=131) before the start of the telemedical treatment. 131 255
- 256 (51.6%) and 98 (38.5%) of the initial 254 participants also responded to the second and third survey,
- respectively. Patients reported a significant improvement of well-being 4-6 and in particular 8-12 257
- 258 weeks after the start of the telemedical appointments (WHO-5 4-6 weeks  $39.60 \pm 21.61$ ; WHO-5 8-12
- weeks  $41.47 \pm 21.26$ ; p < 0.001, the Wilcoxon test was used for comparison with the initial WHO-5 259
- 260 self-report). 8-12 weeks after initiation of the telemedical treatment only 32% (n = 33) revealed very
- 261 poor well-being, indicative of severe depressive symptoms (WHO-5 score≤28).
- Patients were also asked to fill out the Symptom Checklist-90 Revised (SCL90-R) at baseline, and 4-262
- 6 weeks after the start of the telemedical treatment. The mean SCL90 total score for n = 83 (32.68%) 263
- participants was  $107.9 \pm 60.86$  at baseline (1st inquiry, Fig. 1B) with a decline to a mean score of 85.08 264
- ± 61.22 in the second survey (2nd inquiry, Fig. 1B), indicating a significant improvement of 265
- psychopathological symptoms after 4-6 weeks (p<0.001 with a paired Wilcoxon test to compare the 266
- SCL90 total scores of patients who participated in both inquiries). For patients who participated in both 267
- inquiries (n = 86), the means of all three global indices of distress in the first inquiry were above the 268
- critical threshold (T-value ≥ 60, Supplementary Figure 2). The Global Severity Index (GSI) was 66.61 269
- 270 ± 10.31.77% (n = 83) of the study population who participated in both inquiries scored with a T-value
- 271 ≥ 60 suggesting "psychologically measurable distressed cases" (21). In addition, the Positive Symptom
- 272 Distress Index (PSDI) and the Positive Symptom Total (PST) were evaluated as global measures of
- symptom intensity and number of psychiatric symptoms with significant burden. Means of both indices 273
- revealed T-values  $\geq$  60 (PSDI 65.12  $\pm$  8.23; PST 62.02  $\pm$  8.45) substantiating significant mental 274
- 275 distress. Furthermore, all mean values of the nine primary symptom dimensions (Supplementary Figure
- 276 2) exceeded T-values of 60. In particular the subscales for obsessive-compulsive symptoms and
- 277 depression scored even above a T-value  $\geq$  65 (Mean obsessive-compulsive 67.55  $\pm$  10.77; Mean
- depression 67.08 ± 10.61, Supplementary Figure 1), revealing significant burden in the study 278
- population (T  $\geq 1\frac{1}{2}$  SD of mean T-values in a healthy norm group, Franke 2001). All global scales and 279
- 280 nine primary dimension scores were markedly decreased in the second inquiry (p<0.001); a Wilcoxon
- test was used for the comparison of the results of patients with both inquiries completed 281

- (Supplementary Figure 2). In particular T-Values were below 60 for the PSDI (59.45± 10.67) and for 282
- 5 out of nine primary dimension scores (anxiety, hostility, phobic anxiety, paranoid ideation and 283
- psychoticism, Supplementary Fig. 2), indicating a reduction of psychopathological burden for these 284
- 285 dimensions to the range of a healthy norm group.
- 286 The correlations of the WHO-5 self-assessments with the SCL90-R global scores are displayed in Fig.
- 1C. With regard to well-established clinical scales, relationships between the response and explanatory 287
- 288 variables were obtained; for the Clinical Global Impressions Scale (CGI), WHO-5 decreased by 8.51
- 289 per CGI increase to measure the severity of psychopathology and for the Global Assessment of
- 290 Functioning scale (GAF), the WHO-5 increased by 0.70 points per GAF point increase.

## Patients diagnosed with depression profit more from telemedicine psychiatry than those with other 291

## 292 psychiatric entities

313

We next investigated how patients diagnosed with a depressive episode developed under 293 telepsychiatric treatment, as these patients were significantly more severely affected based on clinical 294 judgment than patients with other psychiatric entities: The CGI was significantly higher for patients 295 with depression (4.98  $\pm$  0.89) than for those without (4.70  $\pm$  0.92, p<0.05, Mann-Whitney test, Fig. 296 297 2A). In addition, the GAF was significantly lower for depressive subjects  $(57.46 \pm 10.77)$  than for those participants with other psychiatric issues (62.18  $\pm$  10.77, p<0.05, Mann-Whitney test, Fig. 2B). 298 Depressive patients also scored significantly lower in the WHO-5 in the first inquiry before the start of 299 the telemedical treatment (Fig. 2C, depressive patients 18.80±14.57 versus others 30.92 ± 22.00, 300 301 p<0.001, two-way repeated measures analysis of variance (ANOVA) with post hoc Bonferroni). However, during the course of telepsychiatric treatment the WHO-5 improved for depressed patients 302 303 to a level comparable to patients with other psychiatric disorders, who were clinically less severely ill at the beginning of treatment (Fig. 2C, p=0.22 for inquiry 2 comparing patients with and without 304 depression and p>0.99 for inquiry 3, ANOVA with post hoc Bonferroni). In particular, patients with 305 306 depression reported an improvement of >20% on the WHO-5, while subjects with chronic disorders like personality disorders or hyperkinetic disorders who completed the 2nd and 3rd survey of the 307 WHO-5 indicated a decline in mental well-being (Fig. 2D). We also investigated potentially protective 308 309 or supportive sociodemographic characteristics of depressed patients that were lacking in other 310 patients. However, when examining life and labor situation, education and professional training, 311 children and living situation, as well as debts and the history of criminal assaults, we did not find 312 significant differences (Fig. 2E).

## Satisfaction with telemedicine psychiatry

314 At the end of our observational study, patients were asked to evaluate the telepsychiatric treatment provided during the study period. Most consultations were arranged via phone (89.29%, Table 4) and 315 316 technical problems were rarely an issue (87.50%). More than 80% of participants (81.48%, Table 4) were satisfied with telemedical treatment. 49.07% (Table 4) of subjects experienced telepsychiatric 317 318 counseling as effective as face-to-face treatment. Almost half of patients (49.54%, Table 4) considered using telemedicine in the future again. In particular female patients rated telemedical treatment as 319 320 equivalent to counseling in person (r = 0.413, Spearman's correlation) and expressed their wish to use telemedicine in the future again (r = 0.342, Spearman's correlation). The more telepsychiatric sessions 321 subjects attended the more likely they were to experience telepsychiatry as equal to conventional 322 323 outpatient therapy (r = 0.231, Spearman's correlation). When participants were asked to describe pros and cons of telepsychiatry, half of the participants providing feedback (N=102 statements) missed the 324 personal atmosphere when talking face to face, while a quarter even reported to have missed substantial 325

- information of the conversations due to missing gestures and body language. 16.7% could not describe 326
- any disadvantage at all. 46.1% found telepsychiatry much more comfortable than conventional therapy, 327
- as it was secure to prevent any kind of infection (10.8%) and required less time. Patients also reported 328
- 329 (27.4%) to feel less stressed during telepsychiatric treatment when providing intimate details of their
- biography while sitting in a familiar environment at home. 330

## 4 Discussion

- The current study aimed at longitudinally investigating the applicability and effectiveness of 332
- telemedical treatment in a naturalistic monocentric sample of psychiatric outpatients during the first 333
- waves of the COVID-19 pandemic in Germany. A secondary aim was to identify clusters of 334
- psychopathology and determine sociodemographic features that were indicative of a favorable 335
- response to telemedical psychiatric outpatient treatment. Lastly, the study addressed patients' 336
- perceptions of telemedical treatment. 337
- More than one third of participants was diagnosed with a hyperkinetic disorder, mostly attention deficit 338
- hyperactivity disorder (ADHD) or attention deficit disorder (ADD), probably due to the professional 339
- specialization of general psychiatric outpatient services at the CIMH. Almost a quarter of participants 340
- was diagnosed with a depressive episode as the main diagnosis during the treatment interval of concern. 341
- 342 However, psychopathology in the entire sample, as rated by clinicians, was dominated by symptoms
- of depression and anxiety in a majority of participants at the onset of telemedical treatment. This is 343
- consistent with earlier findings concerning psychological distress linked to the outbreak of the COVID-344
- 345 19 pandemic(22).
- Most participants reported poor well-being and high rates of depression before the onset of telemedical 346
- 347 psychiatric outpatient treatment on the WHO-5 and showed significant improvement 8-12 weeks after
- the initiation of telemedical treatment. Furthermore, the study population showed a significant degree 348
- of psychological distress as measured by the SCL 90-R, both on a global scale (GSI) as well as 349
- 350 concerning symptom intensity (PSDI) and quantitative symptom load (PST). In this line, participants'
- self-assessments via the SCL 90-R revealed a significant burden in all nine primary symptom 351
- dimensions of the SCL 90-R, centering around the subscales for depressive and obsessive-compulsive 352
- 353 symptoms at baseline. After 4-6 weeks a significant reduction of psychopathology as measured by the
- 354 SCL 90-R was observed, partly equivalent to the range of a healthy norm group. Generally, patients'
- self-assessment via the WHO-5 and the SCL 90-R correlated well with observer-rated impressions on 355
- 356 more generic measures of clinical functioning and disorder-severity (CGI, GAF). Thus, the specific
- conditions of telepsychiatric assessment and treatment did not impede the validity and reproducibility 357
- of diagnostic procedures in the study sample. This corroborates earlier findings that the implementation 358
- 359 of patient reported outcome measures via telemedicine is a viable way of assessing psychiatric
- symptoms and psychosocial functioning as well as monitoring clinical changes in order to improve 360
- treatment outcomes (23). 361
- Overall, participants diagnosed with depressive disorders during telemedical treatment were 362
- significantly more affected by a deterioration of well-being and functioning than participants suffering 363
- 364 from other mental disorders. Yet, during the treatment process, patients with depressive disorders
- showed a pronounced improvement, whereas individuals with chronic or non-episodic disorders like 365
- ADHD and personality disorders did not benefit likewise and somewhat counterintuitively showed 366
- a decline in mental well-being on the WHO-5 during the study period. Specific sociodemographic traits 367
- derived from patients' electronic medical records were not associated with this remarkable difference 368 in treatment outcome, although it could be speculated that chronically impaired individuals might be 369
- exposed to more challenging social and environmental conditions (e.g. societal isolation, job 370
- insecurity, downward social mobility). Patients with ADHD and other neurodevelopmental disorders 371

may generally be more vulnerable to a variety of negative health outcomes and increased mortality(24). 372

ADHD symptom severity predicted adherence to preventive measures during the pandemic and higher

psychological distress(25). Yet, it is unknown if the ADHD patients in our sample experienced higher 374

375 or equal levels of distress and higher levels of well-being before the pandemic. Thus, variance and

oscillations of psychopathology in neurodevelopmental disorders that are predominantly chronic by

nature could not be effectively influenced during the study period by telemedical treatment in our 377

sample. In contrast, available data concerning the telemedical treatment of chronic somatic diseases 378

points at an overall positive effect of telemedicine on the management of these conditions (25). 379

Overall, a vast majority of participants reported high satisfaction with and robust acceptance of the telemedical treatment administered during the study period. Roughly 50% of participants, predominantly female, rated telemedical treatment equivalent to treatment provided face to face. This finding seems to be of particular interest as almost 75% of all participants had undergone psychiatric treatment at some point before their participation in this study. Remarkably, patients' satisfaction with telemedical treatment seemed to increase with the number of telemedical consultations. This is in line with findings from a current nationwide multicentric study from Germany where overall good experiences with the telemedical treatment of affective, stress related and somatoform disorders were

## Limitations 389

reported(26).

373

376

380

381

382

383 384

385 386

387 388

390

391

392

393

394 395

396

397

398

399

400

401

402 403

404

405

406 407 There are some limitations concerning the above mentioned results that warrant further discussion. Firstly, the study sample might not be fully representative of the entirety of patients that underwent telemedical treatment during the COVID-19 pandemic at the CIMH. The study sample could be enriched for individuals with an above average willingness to partake in an observational study with repeated surveys. Consequently, severely and extremely mentally ill patients who experience difficulties filling out questionnaires and checklists repeatedly might have been excluded. An earlier study found that older patients and patients with more severe disorders (e.g. schizophrenia) were less likely to use telemedicine, whereas female patients with anxiety and depressive disorders as well as post-traumatic stress disorder (PTSD) more frequently used telemedicine(27). Furthermore, participants were not screened for their cultural or ethnic background. Therefore it cannot be excluded that language or cultural barriers prevented potential participants from being included into the study cohort as described before in a sample of African American patients from North America(7). There is no information regarding the degree of digital literacy in the study sample although it is characterized by a relatively high degree of education. Previous studies demonstrated that healthcare providers' degree of experience with digital technologies is associated with the willingness to use these technologies and the way they are judged by their users (28). Likewise, the acceptance of telemedicine by its users is shaped by the perceived usefulness of the technologies applied, social influence and personal attitude(29).

408 It cannot be ruled out that the significant improvement in psychopathology and functioning observed 409 in individuals with depressive disorders during telemedical treatment merely corresponds to the naturalistic course of a group of disorders that is generally characterized by an episodic course. 410 411 Furthermore, a decrease in distress among the study population during the observation period might be partially linked to the gradual suspension of lockdown measures during spring/summer 2020 and spring 412 413 2021 as a confounding factor. It has been shown that an escalation of lockdown measures during the 414 COVID-19 pandemic and the rapid spreading of the novel coronavirus reliably lead to a deterioration of mental health in the general population within different cultural backgrounds around the world(30– 415 33). However, more recent studies hint at a persistence of distress and burden of psychopathology 416 417 independent from periodic intensifications of lockdown measures<sup>6</sup>. In our study cohort, there was a marked difference in the decrease of symptom load between participants with episodic, mostly 418

- 419 depressive disorders and chronic disorders like ADHD, strengthening the hypothesis that a significant
- part of the psychopathological improvement experienced by a distinct group of participants in our study 420
- truly represents a treatment effect. 421
- Lastly, due to the naturalistic design of our study, there were neither a healthy control group nor placebo 422
- or sham treatments included. The latter might in any case have raised serious ethical concerns during 423
- 424 a global pandemic. Nevertheless, we speculate that the participants in our study were generally more
- affected by psychological distress compared to the general population since the severity of their 425
- symptomatology crossed the threshold for diagnosing one of the above mentioned disorders and was 426
- 427 eligible for psychiatric treatment within the German insurance system. However, we do not know the
- precise pre-pandemic level of psychopathology at baseline. Since a majority of patients that enrolled 428
- in our study had received psychiatric treatment at some time, however not immediately before the 429
- beginning of the study, they might have been at a greater risk for developing clinically relevant 430
- psychopathology during the COVID-19 pandemic, a finding that is also supported by results from a 431
- French cohort focusing on individuals with a history of depressive episodes (34). 432

### 5 **Conclusions**

433 434

435

436

437

438 439

440

441 442

443

444 445

446

447

448

449

450

453

457

Psychiatric telemedical treatment is an effective treatment option for patients with depressive disorders that yielded overall favorable outcomes in the observed group of patients. Although individuals diagnosed with depression in our sample had a higher load of psychopathology in the beginning, they profited most from telemedical treatment compared to participants with chronic neurodevelopmental disorders like ADHD who experienced an additional decline of well-being. The latter finding indicates that future research needs to concentrate on improving telemedical treatment options suited for chronic psychiatric conditions. Our study demonstrated a good match between patient-reported standardized measures of psychopathology and clinicians' assessments during telemedical treatment, indicating that telemedical consultations could be a simple, economic and cost-effective but nevertheless reliable way of monitoring symptom severity and directing treatment choices during the treatment of depressive disorders. This is complemented by the overall high satisfaction of participants with the telemedical treatment they received. Therefore, current research on ecological momentary assessment (EMA) seems to open a promising new avenue towards personalized psychiatric telemedical treatment in the near future.

## 6 **Conflict of interest**

- The authors have no patents pending or financial conflicts to disclose. Anna-Sophia Wahl is a recipient 451
- of the Margarete Wrangell habilitation fellowship and the Branco Weiss Society in Science Fellowship. 452

### 7 **Author Contributions**

- 454 ASW and PP designed the study. TR, PP and ASW acquired data. AB developed the online survey
- tool. TR, TP and ASW analyzed data. OH, HT and AML advised and discussed data. PP, TP and ASW 455
- wrote the manuscript with the help of all authors. All authors have read and approved the manuscript. 456

## **Funding** 8

- 458 ASW is a recipient of the Branco Weiss Society in Science Fellowship and of the Wrangell Habilitation
- Scholarship. Otherwise, this research did not receive a specific grant from any funding agency in the 459
- public, commercial, or non-profit sectors. 460

## 9 Acknowledgments

461

466

469

470

- 462 The authors thank the service and telephone team of the outpatient clinic at the Central Institute of
- Mental Health Mannheim, Germany, under the lead of Volker Nitschke for their help with the 463
- recruitment of study subjects as well as Gerhard Kühne for the help with the analysis of data from the 464
- 465 electronic medical records.

## **10** Data availability statement

- 467 All data are presented in the paper and the supplementary material. For details of the analysis with
- SPSS data can be made available on reasonable request. 468

## References

- 471 1. Sood S, Mbarika V, Jugoo S, Dookhy R, Doarn CR, Prakash N, et al. What is telemedicine? A
- collection of 104 peer-reviewed perspectives and theoretical underpinnings. Telemedicine and e-472
- 473 Health. 2007;13(5).
- 474 2. Siegel A, Zuo Y, Moghaddamcharkari N, McIntyre RS, Rosenblat JD. Barriers, benefits and
- 475 interventions for improving the delivery of telemental health services during the coronavirus disease
- 2019 pandemic: A systematic review. Vol. 34, Current Opinion in Psychiatry. 2021. 476
- 477 3. Bashshur RL, Shannon GW, Bashshur N, Yellowlees PM. The Empirical Evidence for Telemedicine
- 478 Interventions in Mental Disorders. Telemedicine and e-Health. 2016;22(2).
- 479 4. Fu Z, Burger H, Arjadi R, Bockting CLH. Effectiveness of digital psychological interventions for
- 480 mental health problems in low-income and middle-income countries: a systematic review and meta-
- 481 analysis. The Lancet Psychiatry. 2020;7(10).
- 482 5. Barnett ML, Ray KN, Souza J, Mehrotra A. Trends in Telemedicine Use in a Large Commercially
- 483 Insured Population, 2005-2017. Vol. 320, JAMA - Journal of the American Medical Association. 2018.
- 484 6. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in Outpatient
- Care Delivery and Telemedicine during the COVID-19 Pandemic in the US. Vol. 181, JAMA Internal 485
- 486 Medicine. 2021.
- 7. 487 Xue Y, Saeed SA, Liang H, Jones K, Muppavarapu KS. Investigating the Impact of Covid-19 on
- Telepsychiatry Use Across Sex and Race: A Study of North Carolina Emergency Departments. 488
- Telemedicine and e-Health. 2022; 489
- 490 8. Basit SA, Mathews N, Kunik ME. Telemedicine interventions for medication adherence in mental
- 491 illness: A systematic review. Vol. 62, General Hospital Psychiatry. 2020.
- 9. Guaiana G, Mastrangelo J, Hendrikx S, Barbui C. A Systematic Review of the Use of Telepsychiatry in 492
- 493 Depression. Community Mental Health Journal. 2021;57(1).
- 494 10. Bessonova L KEAE et al. Clinical Management of Patients with Schizophrenia Treated with Long-
- Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic. CNS Spectr . 495
- 496 2022;27(230).

- 497 11. Fortier CB, Currao A, Kenna A, Kim S, Beck BM, Katz D, et al. Online Telehealth Delivery of Group Mental Health Treatment Is Safe, Feasible, and Increases Enrollment and Attendance in Post-9/11 U.S. 498
- 499 Veterans. Behavior Therapy. 2022;
- 500 12. Barnett P, Goulding L, Casetta C, Jordan H, Sheridan-Rains L, Steare T, et al. Implementation of 501 telemental health services before COVID-19: Rapid umbrella review of systematic reviews. Vol. 23,
- Journal of Medical Internet Research, 2021. 502
- 503 13. Lyles CR, Wachter RM, Sarkar U. Focusing on Digital Health Equity. Vol. 326, JAMA - Journal of the 504 American Medical Association, 2021.
- 505 14. Primack BA. The WHO-5 Wellbeing index performed the best in screening for depression in primary 506 care. Evidence-Based Medicine. 2003;8(5).
- 507 15. Peveler RC, Fairburn CG. Measurement of neurotic symptoms by self-report questionnaire: Validity of the SCL-90R. Psychological Medicine. 1990;20(4). 508
- 16. 509 Grootenboer EMV, Giltay EJ, van der Lem R, van Veen T, van der Wee NJA, Zitman FG. Reliability and validity of the Global Assessment of Functioning Scale in clinical outpatients with depressive 510 511 disorders. Journal of Evaluation in Clinical Practice. 2012;18(2).
- 512 17. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical 513 practice. Psychiatry (Edgmont). 2007;4(7).
- WHO Regional Office for Europe. Wellbeing measures in primary health care. Report on a WHO 514 18. Meeting, Stockholm, Sweden. 1998. 515
- 516 19. Derogatis L, Savitz K. The SCL-90-R, Brief Symptom Inventory, and Matching Clinical Rating Scales.
- 517 The use of psychological testing for treatment planning and outcomes assessment (2nd ed.). Lawrence
- Erlbaum Associates Publishers. 1999; 518
- 519 20. Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 well-being index: A systematic review 520 of the literature. Psychotherapy and Psychosomatics. 2015;84(3).
- 521 21. Franke GH. Möglichkeiten und Grenzen im Einsatz der Symptom-Checkliste SCL-90-R.
- 522 Verhaltenstherapie und psychosoziale Praxis. 2001;33(3):475–85.
- 523 22. Shi L, Lu ZA, Que JY, Huang XL, Liu L, Ran MS, et al. Prevalence of and Risk Factors Associated
- with Mental Health Symptoms among the General Population in China during the Coronavirus Disease 524
- 2019 Pandemic. JAMA Network Open. 2020;3(7). 525
- 526 23. Kablinger AS, Gatto AJ, O'Brien VC, Ko H, Jones S, McNamara RS, et al. Effects of COVID-19 on
- Patients in Adult Ambulatory Psychiatry: Using Patient-Rated Outcome Measures and Telemedicine. 527
- 528 Telemedicine and e-Health. 2022;
- 529 24. Catalá-López F, Hutton B, Page MJ, Driver JA, Ridao M, Alonso-Arroyo A, et al. Mortality in Persons
- with Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and 530
- 531 Meta-analysis. Vol. 176, JAMA Pediatrics. 2022.
- 532 25. Pollak Y, Shoham R, Dayan H, Gabrieli-Seri O, Berger I. Symptoms of ADHD Predict Lower
- 533 Adaptation to the COVID-19 Outbreak: Financial Decline, Low Adherence to Preventive Measures,
- Psychological Distress, and Illness-Related Negative Perceptions. Journal of Attention Disorders. 534
- 535 2022;26(5).

569

536 26. Wiegand HF BAFM et al. Changes and Challenges in Inpatient Mental Health Care During the First 537 Two High Incidence Phases of the COVID-19 Pandemic in Germany - Results From the COVID Psi 538 Psychiatry Survey. Front Psychiatry. 2022;(13:855040). 539 27. Ainslie M, Brunette MF, Capozzoli M. Treatment Interruptions and Telemedicine Utilization in 540 Serious Mental Illness: Retrospective Longitudinal Claims Analysis. JMIR Mental Health. 2022;9(3). 541 28. Wilczewski H PSOT et al. Perceptions of Telemental Health Care Delivery During COVID-19: A Cross-Sectional Study With Providers, February-March 2021... Front Psychiatry . 2022;(13:855138). 542 29. 543 Harst L, Lantzsch H, Scheibe M. Theories predicting end-user acceptance of telemedicine use: 544 Systematic review. Vol. 21, Journal of Medical Internet Research. 2019. 545 30. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression 546 symptoms in US adults before and during the COVID-19 pandemic. JAMA Network Open. 2020;3(9). 547 31. Niedzwiedz CL, Green MJ, Benzeval M, Campbell D, Craig P, Demou E, et al. Mental health and 548 health behaviours before and during the initial phase of the COVID-19 lockdown: Longitudinal analyses of the UK Household Longitudinal Study. Journal of Epidemiology and Community Health. 549 550 2021;75(3). Pandey D, Bansal S, Goyal S, Garg A, Sethi N, Pothivill DI, et al. Psychological impact of mass 551 32. 552 quarantine on population during pandemics-The COVID-19 Lock-Down (COLD) study, PLoS ONE. 2020;15(10 October). 553 554 33. Wang C, Song W, Hu X, Yan S, Zhang X, Wang X, et al. Depressive, anxiety, and insomnia symptoms 555 between population in quarantine and general population during the COVID-19 pandemic: a casecontrolled study. BMC Psychiatry. 2021;21(1). 556 557 34. Olié E. Dubois J. Benramdane M. Guillaume S. Courtet P. Psychological state of a sample of patients 558 with mood disorders during the first French COVID-19 lockdown. Scientific Reports. 2021;11(1). 559 560 561 562 563 564 565 566 567 568

# Tables and figure legends:

- Table 1. Sociodemographic characteristics of the study population assessing sex, age, marital status, 571
- children, living situation, eduction, professional training, labor and financial situation. N= number of 572
- subjects where information was found in the medical record. The percentage was calculated as (N/N 573
- 574 responded)\*100. M=mean, SD= standard deviation.
- **Table 2.** Table depicting the psychiatric history of subjects including the leading psychiatric diagnosis 575
- documented in the medical record, as well as attempts of suicides and previous psychiatric treatments. 576
- N= number of subjects where information was found in the medical record. The percentage was 577
- calculated as (N/N responded)\*100. 578
- **Table 3.** Table revealing the amount of psychiatric counseling, hospitalization requirements and days 579
- of hospitalization in a specialized psychiatric unit 12 months before the pandemic and during the course 580
- of the study in the Covid-19 pandemic. N= number of subjects where information was found in the 581
- medical record. The percentage was calculated as (N/N responded)\*100. M=mean, SD= standard 582
- 583 deviation.

- **Table 4.** Results of the evaluation of the telemedical psychiatric counseling by the study participants 584
- 585 requesting feedback considering the mode of telemedical treatment, problems that emerged during
- telemedical treatment, overall satisfaction and if subjects are willing to use telemedical offers in the 586
- future. N= number of subjects that provided feedback at the end of the telemedical treatment. The 587
- 588 percentage was calculated as (N/N responded)\*100.
- 589 Figure 1. Results of self-report assessment using WHO-5 and SCL90-R. (A) Results of the WHO-
- 5 Wellbeing Index: Boxplots with scoring details of all individuals participating in the different surveys 590
- (inquiry 1= survey before the beginning of the telemedical treatment; inquiry 2 and 3= surveys 4-6 and 591
- 592 8-12 weeks after start of the telemedical counseling respectively) are shown in the upper panel. In the
- lower panel we compared the results of subjects who participated at least in the first and one 593
- consecutive survey. We found a significant improvement of WHO5 scores during the course of 594
- 595 telemedical treatment (inquiry 1 versus 2, p<0.001, Wilcoxon-test). (B) Results of the SCL90-R. Those
- participants that completed the survey twice (before and 4-6 weeks after start of the telemedical 596
- psychiatry) reported a significant improvement of psychopathological symptoms (significant decrease 597
- 598 of total scores for inquiry 2 versus 1, p<0.001, Wilcoxon-test). (C) Results of the WHO-5 correlated
- 599 to clinical scores such as the CGI and the GAF as well as to all three global indices of distress of the
- SCL90-R such as the GSI, PSDI and PST (A linear regression analysis was performed, β=regression 600
- 601 coefficient). \*\*\*p<0.001. n.s.= non-significant.
- 602 Figure 2. Based on clinical judgment using the clinical scores, CGI (A) and GAF (B) patients
- diagnosed with depression were significantly sicker than subjects with other psychiatric entities (for 603
- both CGI and GAF Mann-Whitney test was used to compare participants with and without a 604
- diagnosis of depression). (C) Although depressive patients scored lower in the WHO-5 than patients 605
- with other psychiatric entities (results inquiry 1 of depressive patients versus others, p<0.001, 606
- ANOVA with post hoc Bonferroni), overall well-being of this patient cohort improved in such a way, 607
- 608 that during the 2nd and 3rd inquiry, WHO-5 total scores significantly raised (inquiry 1 versus 2,
- p<0.05; inquiry 1 versus 3, p<0.001, ANOVA with post hoc Bonferroni) to the same levels as found 609
- in patients without a diagnosis of depression. (D) Table depicting the number of participants 610
- 611 diagnosed with different psychiatric entities and how many of these subjects reported a decline or
- 612 improvement in well-being according to the WHO-5 during the course of the telemedical counseling.

(E) Violin plots showing sociodemographic characteristics for the two cohorts (subjects diagnosed with depression and those without). Using the same different subcategories as described in table 1 we did not find a significant difference between the distribution of sociodemographic characteristics. Results are presented in mean ± SEM; \*P<0.05, \*\*P<0.01, \*\*\*P<0.001.

	N or M (SD)	(%)
Total Number (N) of recruited patients	254	
Female	144	56,7
Male	101	39,8
Anonymous	9	3,5
Age in years (SD)		
Female (N=144)	39,9 (13,3)	
Male (N=100)	37,0 (12,6)	
Marital status (N= 150)		
Single	67	44,7
In relationship with a partner	83	55,3
Children (N=93)		
No children	77	82,8
Children	16	17,2
Living situation (N= 110)		
Living alone	59	53,6
Living with partner	14	12,7
Living with family or friends	31	28,2
Living in supervised accommodation	6	5,5
Education (N=125)		
No school graduation	2	1,6
9 years of school education completed	22	17,6

	1	
10 years of school education completed	40	32,0
>12 years of school education completed	61	48,8
Professional Training (N=130)		
No completed professional training	13	10,0
Completed apprenticeship	70	53,8
Completed academic studies	20	15,4
Apprenticeship on-going	13	10,0
Academic studies on-going	14	10,8
Labor situation (N=107)		
Unemployed	25	23,4
Employed	57	53,3
Retired	8	7,5
Disabled	17	15,9
Financial situation (N=83)		
No debts	53	63,9
Debts	30	36,1


	N	(%)
Psychiatric diagnosis (N= 224)		
Organic mental disorders	3	1,3
Mental disorders due to psychoactive substance use	8	3,6
Schizophrenia, schizotypal and delusional disorders	3	1,3
Bipolar affective disorders	6	2,7
Depressive and recurrent depressive disorders	55	24,6
Anxiety disorders	16	7,1
Reaction to severe stress, and adjustment disorders	15	6,7
Somatoform disorders	2	0,9
Eating disorders	3	1,3
Nonorganic sleep disorders	14	6,3
Disorders of adult personality and behavior	11	4,9
Intellectual disability	1	0,4
Autism spectrum disorders	1	0,4
Hyperkinetic disorders and tics	79	35,3
Neurological diseases causing psychiatric symptoms	7	3,1
Attempted suicides (N=72)		
No history of attempted suicides	51	70,8
History of attempted suicides	21	29,2
Previously treated of a psychiatric disorder (N=163)		
Yes	121	74,2
No	42	25,8


Out-patient treatment (Mean # of doctoral appointments)	M (SD)	
Within 12 months before the pandemic (N=16)	4,56 (5,89)	
During the pandemic (N=254)	4,26 (5,45)	
via telemedicine	3,05 (3,58)	
with personal contact	1,25 (2,98)	
Patients requiring in-patient treatment (N=254)	N (%)	
Within 12 months before the pandemic	4 (1,57)	
During the pandemic	13 (5,12)	
Mean - days of hospitalization (N=254)	M (SD)	
Within 12 months before the pandemic (N=4)	128 (62,20)	
During the pandemic (N=13)	74,54 (46,67)	

Telemedical treatment (N=112)	N	%
via phone	100	89,29
via video chat	2	1,79
via phone and video chat	10	8,93
Technical problems during the telemedical treatment ( $N=112$ )		
Yes	14	12,50
No	98	87,50
Satisfaction with telemedic treatment (N=108)		
Strongly disagree	0	0,00
Disagree	3	2,78
Undecided	17	15,74
Agree	30	27,78
Strongly agree	58	53,70
Telemedical treatment was experienced as effective as therapy in person (N=108)		
Strongly disagree	10	9,26
Disagree	23	21,30
Undecided	22	20,37
Agree	19	17,59
Strongly agree	34	31,48
Patients will consider telemedical treatment in the future again $(N=109)$		

Strongly disagree	19	17,43
Disagree	18	16,51
Undecided	18	16,51
Agree	18	16,51
Strongly agree	36	33,03

Figure 1





Psychiatric diagnosis	Deterioration WHO-5 (N)	Improvement WHO-5 (N)	Improvement >0-10%	Improvement >10-20%	Improvement >20%
Organic mental disorders	0	1	0	1	(
Mental disorders due to psychoactive substance use	1	3	0	1	
Schizophrenia, schizotypal and delusional disorders	1	1	0	0	
Bipolar affective disorders	0	2	1	0	
Depressive and recurrent depressive disorders Anxiety disorders	13	25	6	7	1
Reaction to severe stress and adjustment disorders	2	3	2	0	
Somatoform disorders	0	0	0	0	
Eating disorders	0	0	0	0	
Nonorganic sleep disorders	5	7	2	3	
Disorders of adult personality and behavior	2	2	1	1	
Intellectual disability	0	1	0	0	
Autism spectrum disorders	0	0	0	0	
Hyperkinetic disorders and tics	24	21	7	6	
Neurological diseases causing psychiatric symptoms	2	2	2	0	

